FDA Details Strategies for Addressing Globalization - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Details Strategies for Addressing Globalization
A new report by FDA details the strategies, programs, and other activities the agency is using to address the rise of imported pharmaceutical products and APIs.

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA issued a new report this week that details the activities that the agency is using to address the increased globalization of the industries that it regulates, including pharmaceuticals.

“As our world transforms and becomes increasingly globalized, we must come together in new, unprecedented, even unexpected, ways to build a public health safety net for consumers around the world,” said FDA Commissioner Margaret A. Hamburg, MD, in an Apr. 23, 2012, FDA press release.

Since 2002, imports of pharmaceuticals products and biologics have more than doubled, according to the FDA report, Global Engagement. Foreign-sourced pharmaceuticals now account for approximately 40% of the drugs consumed in the United States, and 80% of APIs in US-consumed drugs are sourced from abroad.

The report outlines a variety of engagement strategies FDA is using in partnership with other agencies, organizations, and coalitions around the world to strengthen global regulatory capacity-building efforts, develop and harmonize science-based regulatory standards, increase awareness about the importance of regulatory systems, and share information and data globally to facilitate rapid identification of and response to public health emergencies.

Part of FDA’s strategy has been to open international offices to increase the agency’s overseas presence. As of 2011, FDA has posts in China (Beijing, Shanghai, and Guangzhou), India (New Delhi and Mumbai), Latin America (San Jose, Costa Rica; Santiago, Chile; and Mexico City, Mexico), Europe (Brussels, London, and Parma, Italy), South Africa (Pretoria), and the Middle East and North Africa (Amman, Jordan).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here